Label: ORACIT- citric acid monohydrate and trisodium citrate dihydrate solution

  • NDC Code(s): 46287-014-01, 46287-014-15, 46287-014-30
  • Packager: Carolina Medical Products Company
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

Drug Label Information

Updated 09/12

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    The product is a clear, colorless solution containing Citric Acid USP 640 mg/5 mL, and Hydrous Sodium Citrate USP 490 mg/5 mL. It also contains Methylparaben NF and Propylparaben NF as preservatives. These concentrations yield 1 mEq of sodium, equivalent to 1 mEq of bicarbonate per mL of solution.

    Close
  • ACTION

    Oral citrate solution is used as a systemic and urinary alkalinizer. Less than 5% of the citrate is excreted in the urine unchanged, since citrate oxidation is to a great extent complete.

    Close
  • INDICATIONS

    ORACIT® is indicated for the treatment of metabolic acidosis. This solution is also useful in conditions where long term maintenance of alkaline urine is needed (e.g. uric acid and cystine calculi of the urinary tract). ORACIT® is also effective in treatment for acidosis of certain renal tubular disorders.

    Close
  • CONTRAINDICATIONS

    ORACIT® is contraindicated in patients with severe renal impairment, oliguria or azotemia, untreated Addison’s disease, adynamia episodica hereditaria, acute dehydration, heat cramp, anuria, severe myocardial damage, and hyperkalemia.

    Close
  • PRECAUTIONS

    The citrate solution should be used with caution in patients with impaired renal function to avoid hypernatremia or alkalosis in the presence of hypocalcemia. Periodic determinations of serum electrolyte levels (especially bicarbonate levels) should be done in patients with renal disease to avoid cardiac failure, hypertension, peripheral and pulmonary edema, and toxemia of pregnancy. The solution should be diluted with water and preferably taken after meals to avoid saline laxative effects.

    Close
  • ADVERSE REACTIONS

    Citrate solution is generally well tolerated when given in recommended doses when the patient has normal renal functions.

    Close
  • DOSAGE AND ADMINISTRATION

    The dose of ORACIT® is 10 to 30 mL, diluted with water, after meals and at bedtime. The dose should be titrated to achieve desired effects.

    Close
  • HOW SUPPLIED

    ORACIT® is supplied in 500 mL bottles (NDC 46287-014-01), 30 mL unit dose bottles, 10 bottles per carton (NDC 46287-014-30), and 15 mL unit dose bottles, 10 bottles per carton (NDC 46287-014-15).

    PHARMACIST

    Dispense in well-closed containers.

    STORE AT CONTROLLED ROOM TEMPERATURE (15° - 30° C)

    Company Logo

    Carolina Medical Products Co.

    Post Office Box 147

    Farmville, North Carolina 27828

    Revised May 1986

    Copyright © Carolina Medical Products Co. 1985

    Close
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - BOTTLE LABEL

    Bottle Lablel

    Bottle Label

    NDC 48287-014-01

    500 mL

    ORACIT®

    ORAL CITRATE (SHOHL'S) SOLUTION

    Contains: Hydrous Sodium Citrate USP 490 mg/5mL; Citric Acid USP 640 mg/5mL; Methylparaben NF; Propylparaben NF; Alcohol 0.25%

    CAUTION: Federal law prohibits dispensing without prescription.

    USUAL DOSAGE: See package insert.

    DISPENSE IN A WELL-CLOSED CONTAINER.

    STORE AT CONTROLLED ROOM TEMPERATURE 15° - 30° C (59° - 86° F).

    BATCH:

    EXP:

     

    Carolina Medical Products Co.

    Post Office Box 147

    Farmville, North Carolina 27828

    Close
  • INGREDIENTS AND APPEARANCE
    ORACIT 
    citric acid and sodium citrate solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:46287-014
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    CITRIC ACID MONOHYDRATE (ANHYDROUS CITRIC ACID) CITRIC ACID MONOHYDRATE 640 mg  in 5 mL
    TRISODIUM CITRATE DIHYDRATE (ANHYDROUS CITRIC ACID) TRISODIUM CITRATE DIHYDRATE 490 mg  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    METHYLPARABEN  
    PROPYLPARABEN  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:46287-014-01 500 mL in 1 BOTTLE
    2 NDC:46287-014-30 10 in 1 CARTON
    2 30 mL in 1 BOTTLE, UNIT-DOSE
    3 NDC:46287-014-15 10 in 1 CARTON
    3 15 mL in 1 BOTTLE, UNIT-DOSE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    Unapproved drug other 05/15/1984
    Labeler - Carolina Medical Products Company (005224175)
    Close